Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dubsky, PC; Singer, CF; Egle, D; Wette, V; Petru, E; Balic, M; Pichler, A; Greil, R; Petzer, AL; Bago-Horvath, Z; Fesl, C; Meek, SM; Kronenwett, R; Rudas, M; Gnant, M; Filipits, M; Austrian Breast and Colorectal Cancer Study Group.
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Eur J Cancer. 2020; 134:99-106
Doi: 10.1016/j.ejca.2020.04.020
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Balic Marija
- Petru Edgar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Neoadjuvant chemotherapy (NaCT) and neoadjuvant endocrine therapy (NET) can reduce pre-operative tumour burden in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer. This prospective translational study assessed the ability of a 12-gene molecular score (MS; EndoPredict®) to predict response to NaCT or NET within the ABCSG-34 trial. Hormone receptor (HR)-positive, HER2-negative samples from patients in the ABCSG-34 randomized phase II trial were selected and EndoPredict testing was performed to generate a 12-gene MS. ABCSG-34 patients were assigned to receive either NaCT or NET based on menopausal status, HR expression, grade and Ki67. Response was measured by residual cancer burden (RCB). Patients selected for NaCT generally had high-risk disease by 12-gene MS (125/134), while slightly more patients treated with NET had low-risk disease (44/83). Low-risk NaCT-treated and high-risk NET-treated tumours responded poorly (NPV 100% [95% CI 66.4%-100%] and NPV 92.3% [95% CI 79.1%-98.4%], respectively]. The 12-gene MS significantly predicted treatment response for NaCT (AUC 0.736 [95% CI 0.63-0.84]) and NET (AUC 0.726 [95% CI 0.60-0.85]). The 12-gene MS predicted RCB after treatment with neoadjuvant therapies for patients with HR-positive, HER2-negative early-stage breast cancer. Tumours with low MS were unlikely to benefit from NaCT, whereas a high MS predicted resistance to NET. This additional biologic information can aid personalized treatment selection in daily practice and builds a strong rationale to use EndoPredict in biomarker-driven studies in the neoadjuvant setting. Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - drug therapy
- Breast Neoplasms - metabolism
- Breast Neoplasms - pathology
- Chemotherapy, Adjuvant -
- Female -
- Follow-Up Studies -
- Humans -
- Middle Aged -
- Neoadjuvant Therapy -
- Prognosis -
- Prospective Studies -
- Receptor, ErbB-2 - metabolism
- Receptors, Estrogen - metabolism
- Receptors, Progesterone - metabolism
- Find related publications in this database (Keywords)
- Breast neoplasms
- Neoadjuvant therapy
- Drug therapy
- Antineoplastic agents
- Hormonal
- Prognosis